

Title (en)  
METHODS FOR TREATING LIPID-RELATED DISEASES INCLUDING XANTHOMAS, CAROTID ARTERY STENOSES, AND CEREBRAL ATHEROSCLEROSIS

Title (de)  
VERFAHREN ZUR BEHANDLUNG VON LIPIDBEDINGTEN KRANKHEITEN, EINSCHLIESSLICH XANTHOMEN, KAROTISSTENOSEN UND ZEREBRALER ATHEROSKLEROSE

Title (fr)  
MÉTHODES DE TRAITEMENT DE MALADIES LIÉES AUX LIPIDES, Y COMPRIS LES XANTHOMAS, LES STÉNOSES DES ARTÈRES CAROTIDES ET L'ATHÉROSCÉLÉROSE CÉRÉBRALE

Publication  
**EP 3886871 A4 20220831 (EN)**

Application  
**EP 19888596 A 20191127**

Priority  
• US 201862773388 P 20181130  
• US 201816225210 A 20181219  
• US 201916409543 A 20190510  
• US 2019063659 W 20191127

Abstract (en)  
[origin: WO2020113041A1] Systems and methods for treating lipid-related diseases including xanthomas, carotid artery stenosis (CAS), and cerebral atherosclerosis (CA) and their complications use direct visualization or imaging techniques to assess the state of the anatomy at issue. A high density lipoprotein composition is made and administered to a patient in order to treat those lipid-related diseases. The administration is continued for a predetermined time or until certain anatomical changes are observed based on imaging, biomarker, or biopsy analysis.

IPC 8 full level  
**A61K 35/16** (2015.01); **A61B 5/00** (2006.01); **A61B 5/02** (2006.01); **A61M 1/02** (2006.01); **A61M 1/36** (2006.01); **A61P 3/06** (2006.01); **A61P 9/00** (2006.01); **A61P 9/10** (2006.01)

CPC (source: EP)  
**A61B 5/02007** (2013.01); **A61B 5/1073** (2013.01); **A61B 5/1075** (2013.01); **A61B 5/4839** (2013.01); **A61K 35/16** (2013.01); **A61M 1/0209** (2013.01); **A61M 1/0218** (2014.02); **A61M 1/3486** (2014.02); **A61M 1/3496** (2013.01); **A61M 1/3687** (2013.01); **A61M 1/3693** (2013.01); **A61P 3/06** (2017.12); **A61P 9/00** (2017.12); **A61P 9/10** (2017.12); **A61B 5/0036** (2018.07); **A61B 5/0042** (2013.01); **A61B 5/055** (2013.01); **A61B 5/4869** (2013.01)

Citation (search report)  
• [IY] WO 2018136866 A1 20180726 - HDL THERAPEUTICS INC [US]  
• [Y] POKROVSKY S N ET AL: "Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity", ATHEROSCLEROSIS SUPPLEMENTS, vol. 30, 2017, pages 166 - 173, XP085276945, ISSN: 1567-5688, DOI: 10.1016/J.ATHEROSCLEROSISSUP.2017.05.004  
• [Y] H. ZACHARATOS ET AL: "Intravascular Ultrasound: Principles and Cerebrovascular Applications", AMERICAN JOURNAL OF NEURORADIOLOGY, vol. 31, no. 4, 4 February 2010 (2010-02-04), US, pages 586 - 597, XP055273825, ISSN: 0195-6108, DOI: 10.3174/ajnr.A1810  
• [Y] GREGORY C MAKRIIS ET AL: "Three-dimensional ultrasound imaging for the evaluation of carotid atherosclerosis", ATHEROSCLEROSIS, ELSEVIER, AMSTERDAM, NL, vol. 219, no. 2, 4 May 2011 (2011-05-04), pages 377 - 383, XP028121253, ISSN: 0021-9150, [retrieved on 20110513], DOI: 10.1016/J.ATHEROSCLEROSIS.2011.05.006  
• See references of WO 2020113041A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2020113041 A1 20200604**; AU 2019389048 A1 20210617; CA 3121552 A1 20200604; CN 113365643 A 20210907; EP 3886871 A1 20211006; EP 3886871 A4 20220831; JP 2022510976 A 20220128

DOCDB simple family (application)  
**US 2019063659 W 20191127**; AU 2019389048 A 20191127; CA 3121552 A 20191127; CN 201980090176 A 20191127; EP 19888596 A 20191127; JP 2021531229 A 20191127